Amivantamab in EGFR Exon 20 Insertion–Mutated Non–Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study - Concepedia

Concepedia

Publication | Open Access

Amivantamab in EGFR Exon 20 Insertion–Mutated Non–Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study

DOI Full Paper Access

597

Citations

31

References

2021

Year

Keunchil Park, Eric B. Haura, Natasha B. Leighl, Paul Mitchell, Catherine A. Shu, Nicolas Girard, Santiago Viteri, Ji‐Youn Han, Sang‐We Kim, Chee Khoon Lee,

Journal of Clinical Oncology

Abstract

Amivantamab, via its novel mechanism of action, yielded robust and durable responses with tolerable safety in patients with <i>EGFR</i> Exon20ins mutations after progression on platinum-based chemotherapy.

References

	Year	Citations

Page 1